Jan 12, 2022 / 04:15PM GMT
David James Adlington - JPMorgan Chase & Co, Research Division - Head of Medical Technology and Services Equity Research
Good afternoon, and good morning, everybody. It's David Adlington again from JPMorgan in London. My pleasure now to introduce David Endicott, CEO of Alcon. David is going to make a presentation, and then we'll break out for Q&A. If you would like to submit a question, there's a button on your screen to do so. But with that, David, thanks for joining us today, and over to you.
David J. Endicott - Alcon Inc. - CEO & Director
Thanks, David. Look, we're excited to be here, even if it's virtual. We always like to be in San Francisco, but this will have to do for now. It seems to be the way of the world.
We're going to talk a little bit today, just a little bit about our innovation agenda for this year. We'll talk a little bit about our longer-term piece. And of course, we'll give guidance with our year-end results next month.
So let me start on Slide 3 in your deck. When we spun out in 2019, our thesis was in essence
Alcon AG at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot